Citations

Mayo Clinic

Clear

727 citation(s) found for "Xu, Jeff L".

The effect of patient age on some new and older IOL power calculation formulas
Sella, Ruti , Reitblat, Olga , Durnford, Kathryn M. , Pettey, Jeff H. , Olson, Randall J. , Hahn, Tara E., Bernhisel, Ashlie , Afshari, Natalie A. , Bernhisel, Ashlie A, Bernhisel, Ashlie A

Acta Ophthalmologica | December 29, 2023 | Volume: 102 | Issue: 5 | Pages: No page available

10.1111/aos.16621 | PMID 38155407 Get It

AbstractPurposeTo assess the accuracy of intraocular lens (IOL) power calculation in different age groups using various IOL calculation formulas.MethodsData from 421 eyes of 421 patients ≥60 years old (ages: 60–69, n = 131; 70–74, n = 105; 75–84, n = 158 and ≥85, n = 27), who underwent uneventful cataract surgery with SN60WF IOL implantation at John A. Moran Eye Center, Salt Lake City, USA, were retrospectively obtained. The SD of the prediction error (PE), median and mean absolute PEs and the percentage of eyes within ±0.25, ±0.50, ±0.75 and ±1.00 D were calculated after constant optimizations for the following formulas: Barrett Universal II (BUII), Emmetropia Verifying Optical (EVO) 2.0, Haigis, Hoffer Q, Hoffer QST, Holladay 1, Kane, Radial Basis Function (RBF) 3.0 and SRK/T. Results were compared between the different age groups.ResultsPredictability rates within 0.25D were lower for the eldest age group compared with the other groups using the EVO 2.0 (33% vs. 37%–53%, p = 0.045), Kane (26% vs. 35%–50%, p = 0.034) and SRK/T (22% vs. 31%–49%, p = 0.002). Higher median absolute refractive errors for all formulas were observed in the oldest group [range: 0.39 D (Haigis, Hoffer QSR)–0.48 D (Kane)], followed by the youngest group [range: 0.30 D (RBF 3.0)–0.39 D (Holladay 1, SRK/T)] but did not reach statistical significance. No significant differences between the groups in the distribution parameter were seen.ConclusionCurrent IOL power calculation formulas may have variable accuracy for different age groups. This should be taken into account when planning cataract surgery to improve refractive outcomes.
Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episo
Saper, Joel R., Kudrow, David, Hirman, Joe, Silberstein, Stephen D., Chakhava, George, Smith, Jeff , Lipton, Richard B. , Dodick, David W.

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s20.001 Get It

Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials (S17.004)
Smith, Timothy R. , Cady, Roger , Schaeffler, Barbara, Smith, Jeff , Biondi, David M., Hirman, Joe, Dodick, David W.

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s17.004 Get It

Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003)
Silberstein, Stephen D., Hirman, Joe, Smith, Jeff , Dodick, David W. , Goadsby, Peter J. , Lipton, Richard B.

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s52.003 Get It

Steroid responsive anti-MOG antibody mediated meningo-encephalomyelitis and optic neuritis (P2.336)
Truong, Melanie, Ortstadt, Jeff, Truong-Le, Melanie , Hitt, Brian D. , Dubey, Divyanshu , Ortstadt, Jeffrey

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p2.336 Get It

75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. (P2.165)
Silberstein, Stephen D., Hirman, Joe, Smith, Jeff , Cady, Roger, Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J.

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p2.165 Get It

Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2 (617)
Gottschalk, Christopher , Tepper, Stewart J. , Cady, Roger , Smith, Jeff , Hirman, Joe, Snapinn, Steve, Dodick, David W. , Friedman, Deborah I.

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.617 Get It

Ubrogepant is Effective in the Acute Treatment of Migraine with Mild Pain (4726)
Adams, Aubrey Manack, Lai, Jeff, Yu, Sung Yun , Finnegan, Michelle , Trugman, Joel M. , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J. , Burstein, Rami

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4726 Get It

A Pilot Study to Assess the Integration of a Unique PROQOL Tool and Early Palliative Care Intervention in the Care of High Grade Glioma Patients and their Caregivers (2633)
Wolfe, Eric, Barrera, Celina, Williamson, Samantha, Farfour, Hannah , Mrugała, Maciej M. , Edwin, Mark, Sloan, Jeff A. , Porter, Alyx B. , Sharma, Akanksha

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2633 Get It

Longitudinal Perception of Prognosis of Patients with High Grade Glioma Compared to their Caregivers and Clinicians (2588)
Wolfe, Eric, Barrera, Celina, Williamson, Samantha, Farfour, Hannah , Mrugała, Maciej M. , Edwin, Mark, Sloan, Jeff A. , Porter, Alyx B. , Sharma, Akanksha

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2588 Get It